SLC6A3 and schizophrenia: By inhibiting the DAT, lumateperone prevents dopamine reuptake from the synaptic cleft, increasing dopamine levels in the mesocortical pathway, which is a typical hypofunction in schizophrenia [10], as shown in Figure 3.